Current Status of Clinical Trials in Head and Neck Cancer 2014

2015 ◽  
Vol 152 (3) ◽  
pp. 410-417 ◽  
Author(s):  
Jeffrey C. Liu ◽  
John A. Ridge ◽  
David M. Brizel ◽  
Brian O’Sullivan ◽  
Ezra W. Cohen ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Current Status

scholarly journals Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment

2021 ◽  
Vol 11 (5) ◽  
pp. 393
Author(s):  
Francesca De Felice ◽  
Daniela Musio ◽  
Vincenzo Tombolini
Keyword(s):  
Clinical Trials ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Therapeutic Strategies ◽  
Check Point ◽  
Clinical Tool ◽  
Cancer Management ◽  
Check Point Inhibitors

In head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test whether induction immunotherapy and/or concomitant immunotherapy and radiotherapy result in improved survival and toxicity outcomes. Here, we present an overview of the most recent concomitant therapeutic strategies for head and neck cancer, focusing on the knowledge available regarding check-point inhibitors. The aim is to present the characteristics of the main check-point inhibitors and to summarize the clinical trials on the combination of immune check-point inhibitors and (chemo)radiotherapy in the definitive HNC setting, in order to provide a useful clinical tool for further research.

Nonstandard Fractionation Schedules in Radiation Therapy of Head and Neck Cancer: A Review

1997 ◽  
Vol 83 (3) ◽  
pp. 633-642 ◽  
Author(s):  
Patrizia Olmi ◽  
Carlo Fallai
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Late Toxicity ◽  
Research Field ◽  
Current Status ◽  
Introductory Overview ◽  
Accelerated Fractionation ◽  
Fractionation Schedules ◽  
Standard Fractionation

The authors present an updated review of the clinical trials on hyperfractionated and accelerated fractionation schedules in radiotherapy of head and neck cancer. The available results in terms of survival and local control, and acute and late toxicity data are summarized in order to show the current status of this research field. The new breed of fractionation schedules that are on study, designed on the ground of new rationales, are presented as well. Finally, an introductory overview of combination therapy including non standard fractionation radiotherapy associated with chemotherapy is reported70.

Sign in / Sign up

Export Citation Format

Share Document